Research and Markets: Leber's Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Pipeline Insights Analysis 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3nzbmg/lebers) has announced the addition of the "Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)-Pipeline Insights" subscription to their offering.

This Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy).

This report provides information on the therapeutic development based on the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  1. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview
  2. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Pipeline Therapeutics
  3. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Therapeutics under Development by Companies
  4. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Discontinued Products
  19. Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Products
  20. Companies Involved in Therapeutics Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/3nzbmg/lebers.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals